89bio (NASDAQ: ETNB)
San Francisco, US · 2 known investors
Find your way into 89bio (NASDAQ: ETNB)
133 people in our graph share verified history with the 89bio (NASDAQ: ETNB) team — schools, employers, funds. One of them is your warm intro.
Teresa Chanunlockedknows Rohan Palekar · together at Johnson & Johnson (overlapped)
×10knows the team · via Johnson & Johnson
knows the team · via Newleos Therapeutics
A clinical-stage biopharmaceutical company developing investigational therapies for patients with liver and cardiometabolic diseases, with a lead candidate (pegozafermin) being evaluated for metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia.
Founders & leadership
RP
Rohan PalekarinFounder · CEO2018–2026Rohan Palekar is founder and former CEO of 89bio, a biopharmaceutical company developing therapies for liver and cardiometabolic diseases. He previously served as President and CEO of Avanir Pharmaceuticals (CNS-focused specialty pharma) and held commercial and operational roles at Medivation and Johnson & Johnson's immunology division.
Investors · 2
In the news
Frequently asked questions
- What does 89bio (NASDAQ: ETNB) do?
- A clinical-stage biopharmaceutical company developing investigational therapies for patients with liver and cardiometabolic diseases, with a lead candidate (pegozafermin) being evaluated for metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia.
- Who founded 89bio (NASDAQ: ETNB)?
- 89bio (NASDAQ: ETNB) was founded by Rohan Palekar.
- Who are 89bio (NASDAQ: ETNB)'s investors?
- 89bio (NASDAQ: ETNB)'s investors include K2 HealthVentures, Longitude Capital.
- Where is 89bio (NASDAQ: ETNB) headquartered?
- 89bio (NASDAQ: ETNB) is headquartered in San Francisco, US.